Citation & Authors
JAMA Ophthalmol. 2025;143(5):400-407.
ABSTRACT · RESEARCH SUMMARY
Research summary
This matched study compared 174,584 patients with diabetes per group. Compared with other non-GLP-1 glucose-lowering drugs, semaglutide was not associated with a significant difference in NAION during the first year, but risk was higher at 2 years (HR 2.39; 95% CI 1.37–4.18), 3 years, and 4 years. Events were rare and the data retrospective; a long-term association should be distinguished from established causality.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
